| Stereochemistry | ABSOLUTE |
| Molecular Formula | C6H14O12P2 |
| Molecular Weight | 340.1157 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)C(=O)COP(O)(O)=O
InChI
InChIKey=XPYBSIWDXQFNMH-UYFOZJQFSA-N
InChI=1S/C6H14O12P2/c7-3(1-17-19(11,12)13)5(9)6(10)4(8)2-18-20(14,15)16/h3,5-7,9-10H,1-2H2,(H2,11,12,13)(H2,14,15,16)/t3-,5-,6-/m1/s1
| Molecular Formula | C6H14O12P2 |
| Molecular Weight | 340.1157 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Fosfructose is a cytoprotective natural sugar phosphate under development by Questcor (formerly Cypros) for the potential treatment of cardiovascular ischemia, sickle cell anemia and asthma. Fosfructose acts by stimulating anaerobic glycolysis which generates adenosine triphosphate under ischemic conditions and improve the cellular energy metabolism in ischemic and hypoperfused tissues. Hypoxia forces ischemic tissue to anaerobic glycolysis for energy, which yields two molecules of ATP per glucose in contrast to 36 molecules of ATP generated during oxidative phosphorylation . Addition of exogenous Fosfructose can produce two more molecules of ATP in an uncompensated anaerobic environment and hence facilitate the recovery of ischemia tissue. Fosfructose breaks down into glyceraldehyde-3-phosphate and dihydroxyacetone phosphate, which will further break down into two molecules of pyruvate and finally produce two molecules of ATP. Other mechanisms include inhibition of the generation of oxygen free radicals by neutrophils, stabilization of cell membranes, and maintainance of the correct xanthine dehydrogenase/oxidase ratio by preventing the depletion of phosphorylated compounds in ischemic tissues. In myocardial infarction patients, FDP can improve the hemodynamic parameters, attenuate ECG proven ischemic injury and arrhythmia, prevent ATP and creatine phosphate depletion from ischemic myocardium, reduce infarct size, and increase survival rate. Exogenously administered Fosfructose has also been proven beneficial for a variety of other ischemic organs, such as liver, kidney, bowel and even brain as a consequence of its ability to penetrate to the blood brain barrier. Fosfructose trisodium had been in phase I clinical trials for the treatment of heart transplant rejection. Fosfructose trisodium had been in phase II clinical trials for the treatment of heart failure, perioperativ eischaemia and reperfusion injury. Fosfructose trisodium had been in phase III clinical trials for the treatment of sickle cell anaemia. However, all these research has been discontinued. In China, FDP has been approved and marketed as a commercial drug.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
800 mkl of PEP (platelet equalized plasma) from healthy or septic rats and 100 mkl of sterile physiologic solution were added in a plastic spectrophotometer cuvette and read in a spectrophotometer (Spectronic, GenesisTM) at 609 nm wave length. After, 100 mkl of adenosine diphosphate 0.2 mM (ADP, Sigma Chemical Co) was added to the cuvette, which was placed in a 37C bath and kept under constant stirring for 5 min. After a 2 min rest, the cuvette was again read at 609 nm, and the aggregation was calculated. To evaluate the effects of fructose-1,6-bisphosphate in vitro, the same test was performed, but instead of the addition of 100 mkl of sterile physiologic solution, 100 mkl of FBP (fructose-1,6-bisphosphate) diluted in sterile physiologic solution at concentrations
of 25, 50, 100, 200 and 400 mM were used to obtain a dose-response curve. Note that the final concentrations of FBP in the tests were 2.5, 5, 10, 20 and 40 mM.
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
Showing 1 to 3 of 3 entries
